Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter StudyJingwen Ai, Ci Qu, Yinong Feng et al.|Clinical Gastroenterology and Hepatology|2021Cited by 73
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter studyJitao Wang, Zhongwei Zhao, Qiran Zhang et al.|Hepatology International|2022Cited by 32
Safety and immunogenicity of COVID‐19 vaccination in patients with hepatocellular carcinoma (CHESS‐NMCID 2101): A multicenter prospective studyXiaolong Qi, Wenhong Zhang, Jitao Wang et al.|Journal of Medical Virology|2022Cited by 12
Correction to: Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter studyJitao Wang, Zhongwei Zhao, Qiran Zhang et al.|Hepatology International|2023Cited by 5
Comparisons of efficacy and safety of 400 or 800 ml bacterial count fecal microbiota transplantation in the treatment of recurrent hepatic encephalopathy: a multicenter prospective randomized controlled trial in ChinaPengfei Zou, Hainv Gao, Yunjiao Bi et al.|Trials|2024Cited by 2